Damien Conover
-
The Friday Five… the line that they'll be able to replace those sales and bring the firm back to growth? [Morningstar analyst] Damien Conover , who covers Pfizer, thinks that the answer to that question is yes. He sees a lot of candidates that are either …
replace those sales and bring the firm back to growth? [Morningstar analyst] Damien Conover , who covers Pfizer, thinks that the answer to that question is yes. He sees a lot of candidates that are either in -
Eli Lilly's CEO Discusses Q1 2013 Results - Earnings Call Transcript
… David Risinger – Morgan Stanley Jami Rubin – Goldman Sachs Seamus Fernandez – Leerink Swann Marc Goodman – UBS Damien Conover – Morningstar David Risinger – Morgan Stanley Presentation Draft version. An edited version will be posted soon …
-
A jury is due to start hearing arguments today about the punitive damages that Johnson & Johnson (JNJ) should pay for damage caused to a South Dakota patient by the company's Gynecare Prolift vaginal ...
… Linda Gross $3.35M. J&J faces 4,000 lawsuits over the product in the U.S., although Morningstar analyst Damien Conover reckons J&J should be able to withstand any further penalties. Post your comment!
-
Merck CEO Discusses Q4 2012 Results - Earnings Call Transcript
… JP Morgan Marc Goodman - UBS Mark J. Schoenebaum - ISI Group Alex Arfaei - BMO Capital Markets Andrew Baum - Citi Damien Conover - Morningstar Presentation Operator Good day everyone and welcome to Merck’s fourth quarter 2012 earnings conference …
-
Scale and Patent Protection Integral Parts of Lilly's MoatDamien Conover : I am Damien Conover , director of pharmaceutical research at Morningstar. I'm ..... Thanks, Dave, and thanks everyone for joining me. I'm Damien Conover , director of pharmaceutical research at Morningstar. Thank …
Damien Conover : I am Damien Conover , director of pharmaceutical research at Morningstar. I'm pleased to be joined by Dave Ricks, head of Eli Lilly's Bio-Medicines group, the largestConover: OK, great. Thanks, Dave, and thanks everyone for joining me. I'm Damien Conover , director of pharmaceutical research at Morningstar. Thank you. -
Big Pharma Dividends Alive and Well… at is the pharmaceutical industry. I am here with Damien Conover , our director of pharmaceutical research, to take a closer look. Damien, thanks for joining me today. Damien Conover : Thanks for having me, Jeremy. Glaser: So, let …
have been looking at is the pharmaceutical industry. I am here with Damien Conover , our director of pharmaceutical research, to take a closer look. Damien, thanks for joining me today. Damien Conover : Thanks for having me, Jeremy. Glaser: So, let's talk a little bit about some of the structural aspects of the pharmaceutical industry -
AstraZeneca PLC Management Discusses Q2 2012 Results - Earnings Call Transcript
… Holford - Jefferies & Company, Inc., Research Division Keyur Parekh - Goldman Sachs Group Inc., Research Division Damien Conover - Morningstar Inc., Research Division Naresh Chouhan - Liberum Capital Limited, Research Division Steve Scala …
-
Pharma Looking Defensive Again… market over the last year. I'm here today with Damien Conover , director of pharmaceutical research, to see if ..... so where it is. Damien, thanks for joining me. Damien Conover : Thanks for having me, Jeremy. Glaser: As a sector …
outperformed the broader market over the last year. I'm here today with Damien Conover , director of pharmaceutical research, to see if there is still value left in these stocks and if so where it is. Damien, thanks for joining me. Damien Conover : Thanks for having me, Jeremy. Glaser: As a sector we used to think of pharmaceutical stocks as being pretty cheap. Quarter-after-quarter we -
Amylin Rejects $3.5 Billion Bid From Bristol; Offer Represents Premium to Firm's Stand-Alone Value
… Amylin ranked Number 18 in Morningstar's annual biotechnology takeout list as our view of the company's strong need for a partner was tempered by fairly disappointing pipeline prospects. Damien Conover , CFA contributed to this note.
-
Significant Upside for Pharma Stock Prices, Dividends… update on the Big Pharma space, I am here today with Damien Conover ; he is our associate director of health care. Damien, thanks for joining me. Damien Conover : Thanks for having me, Jeremy. Glaser : So toward …
an update on the Big Pharma space, I am here today with Damien Conover ; he is our associate director of health care. Damien, thanks for joining me. Damien Conover : Thanks for having me, Jeremy. Glaser : So toward the end of 2011 we saw a pretty big runup in some